An Expanded Access Program for Efgartigimod Treatment in Patients With Generalized Myasthenia Gravis
Recruiting
99 years and younger
All
1 participants needed
1 Location
Brief description of study
This study provides patients with generalized myasthenia gravis (gMG), who are ineligible to participate in a clinical trial, access to efgartigimod treatment before regulatory approval. This expanded access protocol applies to patients with gMG who are not enrolled in an ongoing clinical trial. Enrolled patients will receive cycles of efgartigimod IV 10 mg/kg infused once weekly for 4 infusions.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
Updated on
12 May 2021.
Study ID: 848793
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
